Journal of Clinical Medicine (Aug 2024)

Retrospective Study on the Features and Outcomes of a Tuscany COVID-19 Hospitalized Patients Cohort: Preliminary Results

  • Caterina Silvestri,
  • Cristina Stasi,
  • Francesco Profili,
  • Simone Bartolacci,
  • Emiliano Sessa,
  • Danilo Tacconi,
  • Liliana Villari,
  • Laura Carrozzi,
  • Francesco Dotta,
  • Elena Bargagli,
  • Sandra Donnini,
  • Luca Masotti,
  • Laura Rasero,
  • Federico Lavorini,
  • Francesco Pistelli,
  • Davide Chimera,
  • Alessandra Sorano,
  • Martina Pacifici,
  • Caterina Milli,
  • Fabio Voller,
  • SPRINT Study Group

DOI
https://doi.org/10.3390/jcm13164626
Journal volume & issue
Vol. 13, no. 16
p. 4626

Abstract

Read online

Background: A few months after the COVID-19 pandemic onset, knowledge of SARS-CoV-2 infection and outcomes and treatments blew up. This paper aimed to evaluate the features of a Tuscany COVID-19 hospitalized cohort and to identify risk factors for COVID-19 severity. Methods: This retrospective observational COVID-19 cohort study (1 March 2020–1 March 2021) was conducted on patients ≥ 18 years old, admitted to Tuscany Hospital, and subjected to follow-up within 12 months after discharge. Patients were enrolled at Pisana, Senese and Careggi University Hospitals, and South East, North West, and Center Local Hospitals. Results: 2888 patients (M = 58.5%, mean age = 66.2 years) were enrolled, of whom 14.3% (N = 413) were admitted to an intensive care unit. Smokers were 25%, and overweight and obese 65%. The most used drugs were corticosteroids, antacids, antibiotics, and antithrombotics, all antiviral drugs, with slight differences between 2020 and 2021. A strong association was found between outcomes of evolution towards critical COVID-19 (non-invasive mechanical ventilation (NIV) and/or admission to intensive care) and smoking (RR = 4.91), ex-smoking (RR = 3.48), overweight (RR = 1.30), obese subjects (RR = 1.62), comorbidities (aRR = 1.38). The alteration of liver enzymes (aspartate aminotransferase, alanine aminotransferase, or gamma-glutamyl transpeptidase) was associated with NIV (aOR = 2.28). Conclusions: Our cohort, characterized by patients with a mean age of 66.2 years, showed 65% of patients were overweight and obese. Smoking/ex-smoking, overweight/obesity, and other comorbidities were associated with COVID-19 adverse outcomes. The findings also demonstrated that alterations in liver enzymes were associated with worse outcomes.

Keywords